dual angiotensin II type 1 receptor antagonist/peroxisome proliferator-activated receptor gamma agonist program (Pfizer)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Namedual angiotensin II type 1 receptor antagonist/peroxisome proliferator-activated receptor gamma agonist program (Pfizer)
Drug Alias Namedual AT1 antagonist/PPAR gamma agonist program (Pfizer)PF-120PF-135
ClassificationSmall molecules
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsPeroxisome proliferator-activated receptor γ agonists
TargetsPeroxisome proliferator-activated receptor γAngiotensin II Receptor Type 1
Therapy Area/IndicationsSyndromeHypertriglyceridemiaDiabetes Mellitus +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsSyndromeHypertriglyceridemiaDiabetes Mellitus +[4] 

Other Information

ATC CodeN/A
Related LinksN/A